Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Active, not recruiting · Phase 2 · NCT05853575
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
At a glance
- Research payments reported, 2025
- $160,763
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- Adagrasib (drug)
- Dates
- Started 2024-02-01; completion 2026-11-30
- Results posted
- Not yet
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
From ClinicalTrials.gov, last updated 2026-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $160,763 in research payments for this study in 2025 (4 payments).
Products named: Krazati
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lawrence E. Feldman Hematology & Oncology · Chicago, IL
- January E. Fields, MD Medical Oncology · Hays, KS
- Mark A. Klein, MD Hematology & Oncology · Minneapolis, MN
- Michael J. Kelley, MD Hematology & Oncology · Durham, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Durham VA Medical Center $52,150
- Minnesota Veterans Medical Research and Education Foundation $46,728
- VA Medical Center Hines $34,000
- Midwest Biomedical Research Foundation $27,885
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.